Welcome to Hogwarts. I'm Matt Taylor, the U.S. Medical Supplies and Devices Analyst here at Jefferies, and I have with me the management team of Insulet. We have Ashley McEvoy, who's the CEO, and Divakar Ramakrishnan, who's the head of R&D, new head of R&D. We're going to have some time to talk strategy, to talk innovation, and a full 25 minutes for Q&A. Let me get started here, Ashley. Insulet's historically been such a dominant force in the insulin pump and AID space, and have been driving basically two-thirds of the market growth over the last five years. Maybe start by just talking a little bit about your TAM and the growth that you see there, and how you view your overall competitive position and the long-term growth runway for the company.
Yeah, Matt, thanks. We do enjoy a strong market-leading position in one of the largest, fastest-growing end markets in med tech. We are coming up on our 11th consecutive year of 20%+ revenue growth in a recurring business model. Obviously, we have full intentions to extend that market-leading position, really by continuing to focus on a couple things which are our durable competitive advantage. The first is, as category leader, we generate two-thirds of the category growth. Our primary focus is bringing people from the MDI category into the AID category. We have more than 50% of the industry's SG&A dedicated to educating clinicians around the AID category. You heard me talk around on quarter three call that we have over 34,000 prescribers now writing for Omnipod, which is up over 20%, and that really also enables our customer base, which is up over 20%.
In addition to SG&A, we unleash the power of brand. Brand is one of our moats. We have the largest, highest brand awareness in the category. We are the number one recommended brand in the category and the number one most requested in the category. Number one most prescribed and most requested. Then we invest a lot in manufacturing 100 million of these every year. We've been doing automation, advanced automation for over a decade. We're on track to have our third plant up and going in a couple years, and this really enables kind of scalable COGS at a very competitive COGS and gross margin. Then we take all that and we have unrivaled financial horsepower, and that allows us to continue to invest ahead of the curve, both in supply chain, as well as commercial, as well as innovation.
I'm really thrilled to have Divakar. He's just joined, spent many years, 20 years at Lilly, years at Convatec. Welcome aboard. He's got a big wish list on innovation. Obviously, we have a very competitive pipeline. You've heard me talk about that. He's going to execute that. More importantly, he's going to replenish and really bring future back.
Thank you, Ashley. I first want to go back to Ashley's point about our competitive moat, our manufacturing scale. Just to put it in context, 100 million devices, you're wondering, so what does that mean? I would say if you're a durable pump manufacturer, for every durable pump you make, we have to make 250 - 500 more pumps for every one of them. That is a muscle tissue. I was at Lilly, Convatec, making 300 million devices at Lilly, and then at Convatec, we were making 1 billion, of which a big chunk was infusion sets for durable pump companies. That manufacturing expertise does not happen overnight. You do not design the product and then say you're going to scale it. You actually have to build that design for manufacturing into the design, and you need to have the manufacturing expertise right now in-house.
That is what got me really excited when I looked at Insulet. That's expertise that most companies learn through the school of hard knocks. We've had 10 - 15 years to do that, and that is a huge competitive moat for us. That is number one. Number two is another thing that helps us on innovation is what you see typically is the pod, but there's a whole connected ecosystem around it. Now, we have a few million lines of code connecting the pod with an algorithm, with the apps on multiple phones, right? We also have a data and cloud system that provide insights. Just to give you a sense of the scale of this system, we have 100 million automated decisions coming into our cloud every day, about a terabyte of data per month, right? What does that data mean?
That data then drives us to give actionable insights. Those insights drive engagement at a people with diabetes level and also with the providers. So that is our second moat. Both these moats, the manufacturing moat and the connected ecosystem moat, are what help us position us for a continuous wave of innovation. As we have already disclosed, we have our best ever pod coming out next year, which is Omnipod 6. More than happy to share more with you. Then right after that, a major unlock of our taking our pod and making it simple enough so that people with type 2 diabetes can use it with absolutely no settings, no manual efforts. So that's—
No bolusing.
No bolusing. Those are like amazing things we are bringing in. Then as Ashley said, we have got a whole next generation horizon of products where we are really looking at not just that the pod is the product, but the entire connected ecosystem. So when you start providing insights and engagement, you not only can look at insulin therapy, but also go where insulin therapy is going, which is diabetes therapy is going into cardiometabolic health. There are adjunctive therapies, right? Today, a lot of people are using GLP-1, some people are using SGLT2s. These are all important medicines based on your risk factors. So the connected ecosystem positions us to play not only in AID, but also with adjunctive therapies that are going to become a standard of care along with AID.
Great. Well, maybe I will key off of sort of the innovation theme and roll it into a market and strategy question. So, you have talked about, and some of your competitors have also talked about the fact that innovation can really drive market growth. There is a lot of innovation coming from you and from peers over the next couple years. Maybe talk about the potential for things like Omnipod 5 and a fully closed loop to drive growth, and then I want to dig deeper on what those innovations actually mean.
Yeah, thanks, Matt. I mean, as market leader, obviously, we look at what matters most in the market and what are the big unmet needs to unlock, and there is really three things that matter to this market. The number one is you have got to deliver good outcomes. Two is you have to reduce the burden of diabetes. Living with diabetes, chronic progressive disease, never get a break from it. Third is really remove barriers to access. So all of our portfolio of innovation addresses those three things. It is no surprise that we are the market leader because we do all of those in a superior, simplified customer experience.
At the end of the day, what docs ask for and what people with diabetes ask for is, "I want to have improved quality of life, and I want to feel as normal as possible." So make it as less intimidating as possible. So with that, Divakar will share how we are doing Omnipod 6 and our fully closed loop, and after that.
Omnipod six, like I said, best ever compared to the five other generations we've had. Key components, first of all, we already shared the compelling clinical data we have. What's very particular about it is it's amazing data, really good time in range, that's a key metric we use, with 40% less effort by way of boluses. That means the person has to work less and have more time for other things. That is a core clinical component of it. The second one is we have an anywhere antenna on this system, so effectively makes it easier for people to position their pods relative to the CGM, the CGM sensor. That is critical. The third is we have over-the-air update. For the first time, physicians are not going to have to deal with the complexity of prescribing for patients.
They had to maintain multiple inventories before for a pod that works with one particular CGM versus the other, and they don't have to worry about the prescribing situation. That is Omnipod 6, some of the features I'm able to talk about today. That's extremely compelling from Omnipod 6 perspective. The more exciting one is what comes after that. The key unlock for us is to take a really advanced therapy of insulin therapy and make it simple enough so that you don't need advanced expertise to use it as a patient and to prescribe it as a primary care physician. That is a key unlock we are driving with our fully closed loop. No settings, number one. No bolusing, number two. And training done in roughly 40 minutes by the person with diabetes.
Imagine how much we are reducing the barrier to prescribe from a primary care physician perspective. And the huge benefit you get for a type 2. In the history of insulin and diabetes therapy, in the early 2000s, you all will remember endocrinologists always talked about insulin analogs being the standard of care. Then came Lantus, our basal insulin from Sanofi. So really good therapy, you know. The key unlock there was it made it easy to use by the person with type 2 and made it very easy to prescribe, and that drove a massive adoption. That is the same feature we want to do for people on multiple daily injections. That is a major innovation coming, and beyond that, we definitely have a next-generation platform. There, we are actually looking at not just the pod.
Obviously, want to continue to lead the form factor. Want to increase capacity, increase wear time, like everybody else is doing, but do that along with the entire ecosystem. So, we might have talked about our Discover system that we have launched. You've all heard, it's that data insight analytic system. What it does is it provides all this data, converts it to actionable insights. We have an abstract already submitted for the diabetes conference in February, ATTD, where we show that this improves time in range because users with diabetes change their behaviors. They change their settings in consultation with the HCPs. What we're also going, that horizon is about not only simplifying your experience, but giving you actionable insights so that you're engaged.
That engagement drives trust, and that engagement and trust not only helps therapies like AID, but it also is going to help with adjunctive therapies. Most of diabetes care is becoming cardiometabolic. There are going to be other medicines. That is why I am super excited.
Great. Ashley, maybe just remind us the timelines for Omnipod 6 and fully closed loop, and when we might actually see them start to impact the numbers.
Yeah, thanks, Matt. We are on track to launch Omnipod 6 next year, and then the following year, we will follow up with what Divakar was showing is our, which we believe will be the industry's first fully closed-loop system.
Great. I wanted to touch on a couple real hallmarks for the company. You have really led in ease of use and pioneered pharmacy. Those are big advantages. Maybe talk about how some of these innovations will continue to extend your lead in ease of use, and we can start there.
Yeah, let me kind of start, and I'll have Divakar join. Again, to the notion of improving outcomes, reducing burden, and removing barriers to access, obviously, we pioneered this highly disruptive form factor. We're going to be on our sixth generation. We manufacture at scale, and the market has voted that this highly simplified, superior customer experience is what is the most attractive for people with diabetes. We have a life cycle management of a pipeline on that. The second you've heard me talk about is algorithm improvement. Why algorithms? It's really about making it simpler, improving time in range. Our most recent algorithm improvement we just launched in the U.S., which we're in full market release right now, lower set point, but it keeps people 30% more in automated mode. Next year, when we launch Omnipod 6, again, improved time in range.
Our early clinical data showed 76% time in range, but 40% less bolusing. Then we will work our way to absolute, Matt, full automation, which is as close to a CGM experience as you can get. You put it on, there's no settings, there's no bolusing, and you couple that with our data management system called Discover, which gives you real live-time data, all the data that we've got 35,000 people using Discover right now, and 5,000 clinicians. That was two weeks ago. It goes up every week, Matt. We are rolling this out globally. Really, it makes sense. I mean, if you think about your watch, you think about your Oura Ring, you get more engaged. The more data you get, the more confident you get. We have better retention data. We think that combination is a superior customer experience going forward. Do you want to add anything to that?
Yeah, I think, first, we are going to use our moats of scale and this ecosystem that Ashley just talked about, and we're going to build our innovation based on the reusable components we have there. That's going to help us speed up innovation. That's how we are able to maintain the cadence of innovation. That's number one. As Ashley said, I'm just going to repeat, it's about taking a very advanced therapy, right, and making it simple enough so that you don't need advanced expertise to use it or prescribe it. We have this happening in subsequent generations, a continuous innovation engine. It's not just being done at the pod level or the algorithm level. We are going to do it at all the different layers. That's how we're going to sort of keep driving this velocity. Yeah.
Yeah, just to build on that, it is kind of interesting. People do not necessarily recognize it. Our pod connects to obviously the phone, mobile phone, also connects to sensors, also connects to the cloud. The brain of our pod is on the pod, it is not on the phone. We get visibility to every five minutes we deliver insulin. We take all of that data, and it is what has enabled us to have one of the industry's largest real-world evidence diabetes datasets. We take that data through Omnipod Discover, now launching, and share that data that is very personalized with each person with diabetes, so again, they can make the best decisions, get more confidence, and get better time in range. That is, we are very much in the early innings of doing that.
Then maybe, Ashley, what I can say is, as I have looked at this system relative to many other systems in the industry, many of them were originally designed with the healthcare provider in mind. It came from the pacemaker industry and others. When you look at some of those dashboards, they are extremely complicated. What we have done is taken that same user experience that you talked about, which we led with our product, it is now also showing up in our Discover platform.
If you look at that dashboard, both the physician dashboard and the patient dashboard, they are using the latest cutting-edge gamification approaches, et cetera, so that people can engage. Even for the physicians, primary care physicians, really, we know that their lives are busy. To give them a complete population level index for the patients who need a lot of help versus different levels of help, we are able to give them that sort of insight so that their life is easier.
Great. Maybe we could roll this into the theme of type 2 retention, because there has been some early challenges with that. I know you are making some changes to work on supporting those primary care docs, and it seems like these innovations could really help with that even further. Maybe we could start with what has happened this year, what you are doing to focus on improving that, and then how these innovations could further help that.
Yeah, no, thanks, Matt. I mean, I would first start with the attractiveness of the type 2 market. It's going to be the largest market around the world. We've spent 25 years in type 1. We're about two years into type 2. I will tell you a couple of things. We had some execution challenges that we had in the U.S. We've addressed those in quarter three. Now, those aren't going to be immediately improved like a hockey stick in a month, but they're absolutely going to pay dividends for next year going forward. We changed our sales force incentive from NCS into retention. We added customer care clinical retention specialists. We also, we had Discover, is what Divakar mentioned, which enabled stronger retention. What did I forget?
[inaudible].
We implemented a new CDP platform, and we changed the sampling program for our pods to have a prescription with it, pardon me, as well as healthcare insurance. When we looked at territories, Matt, where they were abiding by our sample best practice, if you will, our retention data was outstanding. Now we're just scaling that nationwide. When I think ahead for the type 2, what's going to win, Divakar shared a lot of analogs from the insulin world, is making it as simpler and user-friendly as possible. This is a burdensome disease. It's a chronic progressive disease. Again, having the winning form factor, having an algorithm that makes you do the least amount of work, and having a patient engagement platform that is extremely user-friendly, very gamified, that makes you feel like as close to a normal being as possible. Do you want to add anything?
No, that's pretty much, you covered it. Thank you.
Well, I wanted to also talk about pharmacy, which I think is part of this access moat. You have a number of competitors coming into the pharmacy. Maybe talk about how your position, and I know you've done some contracting recently, can help to defend against competitors coming in.
Thank you, Matt. We pioneered the pharmacy channel almost a decade ago, because we wanted, again, from a consumer experience, you pick up your therapy where your insulin is. We put a disproportionate amount of volume through the pharmacy channel. As a result of that, we have good leverage, if you will. Most importantly, let me kind of take a step back, which is the AID category with payers is very attractive relative to MDI from a clinical and an economic value proposition. It prevents people from going into hospitals with DKA. It prevents people from going low. The economics of that relative to an annual therapy of being on Omnipod is what makes it so attractive for them to get behind the category in general.
The third thing is we, as the number one most prescribed Omnipod and the number one most requested Omnipod, PBMs clearly take that into consideration for member satisfaction. They don't want to alienate their member base. Also, our strategy that we've deployed has been very intentional to expand the category. We haven't chosen to be exclusive. We want an open choice market because we know we win. We anticipate, Matt, yes, competitors have entered the channel. They've been disciplined on pricing too. We anticipate pricing to remain pretty durable and consistent in the future. We, again, think it's a win-win for patients and for the ecosystem that we're in.
Thank you for that. Maybe I will shift gears. I wanted to ask you about some commercial initiatives. You just recently completed a U.S. sales force expansion, about 25%, I think, that you expanded in Q3. Can you talk about how that could start to bear fruit and the goals of that expansion specifically?
Yeah, sure. Thanks, Matt. We talked a little bit about what drives the market and our leadership in SG&A. We deployed that. We built the industry's largest field force. I am really pleased to see that they have all been clinically trained, so they are selling the science with comfort and confidence. We are going to get benefits from that going forward. We have been expanding our prescriber base, so we had two sales force expansions in two years. It takes some time. It takes like six months to get to full productivity of those. We are always modifying sales force compensation. I spend a lot of time in the field. I was in Guy's and St. Thomas yesterday. They have a waiting list, 370 patients to go on AID therapy. We are triaging all the training for them. They are one of the largest writers for AID in the U.K.
Again, I just think that one of the biggest unlocks of the category, in addition to innovation that Divakar is cooking on, is how we get more prescribers, get confident on writing, particularly the PCP audience, and we have already started to do that. Then also make people with diabetes aware of the category. So we do a lot of direct-to-consumer education and direct-to-HCP education to make them aware of the benefits of AID relative to the MDI category.
Super. Also wanted to touch on international. So you had a big year internationally last year, some tougher comps that will moderate growth, but maybe talk about your strategies to sustain international growth going forward beyond this period.
Yeah, thanks. It's great to be here in London, I have to say. Spent yesterday with my team and in the field. This team is on fire. I mean, we're on track to surpass $1 billion this year. We've had seven consecutive quarters of 30% growth. They've been following a very disciplined playbook that will continue into the future, albeit comps will be high, so it'll be at a moderated pace going forward. But one, that's about market development, like in the example in the NICE guidelines, getting behind the science. We've done a lot of clinical trials that show the benefit of AID therapy relative to MDI. It's a superior clinical and economic value proposition. The NICE guidelines reflect that. Super proud of the U.K. They lead the world in penetration in pediatrics. We have 80% penetration on AID in peds, only 24% in adults.
Now they're getting after adults. So they're taking that playbook, Matt, around penetration and market development. We launched Omnipod 5 internationally. Now we're going to exit this year around 80% conversion. They're really good at selling innovation. Then the third is really opening up new markets. So right now we're in Spain. We've got over 400,000 people with diabetes in España. Very pleased to be able to take our superior value proposition to Spain. We just started in the Middle East with Omnipod 5. Obviously, that area has been challenged early in the year, but we think three years from now, five years from now, it's going to pay dividends. So they're just really sticking with that playbook. They're preparing for him to get innovation next year. We are bringing phone control. We are going to be bringing Omnipod 6. We are integrating now with Libre 3 Plus. I just think a couple years from now, it's going to continue to really bring a lot more people into the category.
Great. Maybe I'll just ask one about numbers and just have you talk a little bit about your LRP through 2028. Could you talk about the goals at a high level and your confidence to continue to track towards those goals?
Yeah, Matt. I would tell you, we are going to share on our quarter four call in February our guide for 2027, and we will give a look at our long view plan on the category as well as our opportunity. What I can tell you now is AID is one of the fastest-growing, largest TAMs and end markets in med tech. We have very strong clinical and economic value proposition relative to MDI. 80% of the volume comes from MDI. Yes, there will be more folks will be trying to come with their Omnipod knockoffs next year. We have been preparing for this. We welcome competition. We are going to continue to do our job, and our job is to continue to extend and build the category. We have full confidence that that trend will continue to happen.
I still believe that we can deliver top-tier revenue growth, expanded profitability, and very unrivaled free cash flows, which lets me give him more money to keep reinventing and bring more people into the category and make sure that we can keep pace with the emerging demand. As I said, we are building our third plant right now, as well as continue to invest in commercial infrastructure to build the market and to make sure that we educate clinicians to get them more confident and get people with diabetes more confident to come into the AID category. Thanks, Matt.
Thank you. That is a good place to end. Thank you so much, and thanks, everybody, for your attention and interest in Insulet.
Thank you.
Thank you.